Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must be a recipient of aT cell depleted unrelated or HLA mis-matched related HSCT for the treatment of a malignancy or immunodeficiency disease.
Patients must have an ANC \> or = to 1500 cells/ul on the day of first treatment.
Patients with acute or chronic leukemia, or MDS prior to transplant must be in remission defined as \<5% blasts in the bone marrow.
Patient with must be in remission.
Patient must be Hepatitis B surface antigen negative pre transplant.
Patients must have adequate cardiac function defined as a left ventricular ejection fraction at rest of \>50% documented pre-transplant.
Patient may be of either gender and of any ethnic background.
Patient may be of any age. There is no upper age restriction.
Patients or their guardians must be able to understand the nature and risk of the proposed study and be able to sign consent.
You may not be if
Karnofsky score \<70%
Female patients who are pregnant or lactating.
Evidence of EBV-LPD or circulating EBV copy number \>1000.
Active uncontrolled bacterial or fungal infection.
Prior history of Hepatitis B infection or Hepatitis B surface antigen positivity pre transplant.
HIV-1,2 sero-positive patients.
Patients or guardians not signing informed consent.
Patients with prior allergic reaction to Rituximab or other murine monoclonal antibody.
Patients taking other investigational agents under another protocol unless discussed and approved in advance by Genentech and the IDEC Therapeutic Director.
Clareo Health | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
